Latest Insider Transactions at Kymera Therapeutics, Inc. (KYMR)
This section provides a real-time view of insider transactions for Kymera Therapeutics, Inc. (KYMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kymera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kymera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
400
-0.53%
|
$18,000
$45.0 P/Share
|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.53%
|
$800
$2.08 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
4,385
-100.0%
|
$171,015
$39.05 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
4,385
+50.0%
|
$43,850
$10.34 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
615
-100.0%
|
$23,985
$39.07 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
615
+50.0%
|
$6,150
$10.34 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
46,137
-20.53%
|
$1,614,795
$35.74 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,137
+27.63%
|
$92,274
$2.08 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$300,000
$30.05 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$100,000
$10.34 P/Share
|
|
Jan 04
2024
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,295
-8.79%
|
$72,490
$22.58 P/Share
|
|
Jan 02
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+1.44%
|
$18,000
$2.08 P/Share
|
|
Nov 03
2023
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
197,699
+3.64%
|
$2,767,786
$14.07 P/Share
|
|
Nov 03
2023
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+1.61%
|
$40,000
$2.08 P/Share
|
|
Nov 02
2023
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
216,406
+5.65%
|
$2,380,466
$11.64 P/Share
|
|
Aug 08
2023
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+2.0%
|
$24,000
$2.08 P/Share
|
|
Jun 02
2023
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.0%
|
$20,000
$2.08 P/Share
|
|
May 22
2023
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+50.0%
|
-
|
|
Mar 02
2023
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,370
-0.65%
|
$42,470
$31.14 P/Share
|
|
Mar 02
2023
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,298
-0.86%
|
$40,238
$31.14 P/Share
|
|
Mar 02
2023
|
Elaine Caughey Chief Business Officer |
SELL
Open market or private sale
|
Direct |
714
-1.82%
|
$22,134
$31.14 P/Share
|
|
Mar 01
2023
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,750
+18.31%
|
-
|
|
Mar 01
2023
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+19.79%
|
-
|
|
Mar 01
2023
|
Elaine Caughey Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,557
+34.89%
|
-
|
|
Jan 12
2023
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
18,897
+0.48%
|
$585,807
$31.24 P/Share
|
|
Jan 12
2023
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
21,592
-2.37%
|
$647,760
$30.29 P/Share
|
|
Jan 12
2023
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
77,128
-1.53%
|
$2,313,840
$30.29 P/Share
|
|
Jan 12
2023
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
98,720
-1.95%
|
$2,961,600
$30.29 P/Share
|
|
Jan 11
2023
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
22,110
+0.51%
|
$641,190
$29.89 P/Share
|
|
Jan 11
2023
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
6,071
-0.66%
|
$176,059
$29.96 P/Share
|
|
Jan 11
2023
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
21,683
-0.43%
|
$628,807
$29.96 P/Share
|
|
Jan 11
2023
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
27,754
-0.54%
|
$804,866
$29.96 P/Share
|
|
Jan 03
2023
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Dec 15
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
717
-0.08%
|
$21,510
$30.0 P/Share
|
|
Dec 15
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
2,561
-0.05%
|
$76,830
$30.0 P/Share
|
|
Dec 15
2022
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
3,278
-0.06%
|
$98,340
$30.0 P/Share
|
|
Dec 14
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
82,889
-1.71%
|
$2,652,448
$32.28 P/Share
|
|
Dec 14
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
296,077
-1.13%
|
$9,474,464
$32.28 P/Share
|
|
Dec 14
2022
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
378,966
-1.42%
|
$12,126,912
$32.28 P/Share
|
|
Dec 08
2022
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.71%
|
$20,000
$2.08 P/Share
|
|
Nov 03
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
21,085
-2.06%
|
$632,550
$30.0 P/Share
|
|
Nov 03
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
75,312
-1.38%
|
$2,259,360
$30.0 P/Share
|
|
Nov 03
2022
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
96,397
-1.72%
|
$2,891,910
$30.0 P/Share
|
|
Nov 02
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
27,038
-2.58%
|
$811,140
$30.02 P/Share
|
|
Nov 02
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
96,581
-1.74%
|
$2,897,430
$30.02 P/Share
|
|
Nov 02
2022
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
123,619
-2.16%
|
$3,708,570
$30.02 P/Share
|
|
Nov 01
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
16,848
-0.79%
|
$505,440
$30.83 P/Share
|
|
Nov 01
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
60,182
-0.54%
|
$1,805,460
$30.83 P/Share
|
|
Nov 01
2022
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
77,030
-0.66%
|
$2,310,900
$30.83 P/Share
|
|
Oct 31
2022
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
26,383
-2.41%
|
$791,490
$30.23 P/Share
|